The cold, dry air of winter brings challenges for those with chronic hand eczema. Chronic hand eczema (CHE), defined as hand ...

Looking for LED light therapy that is practical, non-invasive, and designed for real-world results? This guide focuses on ...

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

After eight weeks, 75% of participants treated with the Corvus pill, called soquelitinib, achieved at least a 75% improvement ...

The company will aim to enroll 50 cats in the study. A biopharmaceutical company is looking for ways to slim down household pets. Okava Pharmaceuticals, a San Francisco based company, plans to ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

Explore the most influential drug approvals of 2025, highlighting FDA-cleared therapies that impact public health and clinical care.

Man scratch oneself, dry flaky skin on hand with psoriasis vulgaris, eczema and other skin conditions like fungus, plaque, rash and patches. A recently approved injectable eczema drug provides quick ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies. Johnson & Johnson has stopped a Phase ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...